A new study offers insights into the relative efficacy of various treatments for alopecia areata (AA), suggesting that ...

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune ...

Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...

What are Janus kinase inhibitors? Janus kinase inhibitors (including tofacitinib) are a class of medications which reduce inflammation in the body. Tofacitinib is currently being used in autoimmune ...

New Janus kinase inhibitors may benefit more patients with MF given their reduced myelosuppression, a study found.

And it was thought that since the first JAK that came to market was what we called a pan-JAK inhibitor, meaning it appeared to inhibit JAK3 preferentially, but oh, then JAK1, oh, then JAK2, that ...

VIDEO: JAK inhibitor adherence key to getting ‘appropriate balance between risk and benefit’Editor’s note: This is an automatically generated transcript. Please notify [email protected] if ...

Some previous studies, including the ORAL Surveillance randomized trial, have shown moderately greater cancer risks with JAK inhibitors versus TNF inhibitors. But some other analyses of real-world ...

A novel dual Janus kinase/protein kinase inhibitor alleviates rheumatoid arthritis at higher doses without causing lipid or creatine kinase changes.

We’re bombarded with too many horror stories of irreversible hair loss and too few success stories of hair recovery. It can feel like one of our most important jobs, specifically as a Black woman, is ...

Effective treatment for hair loss begins with finding the cause. To get an accurate diagnosis, it helps to see a board-certified dermatologist. These doctors have in-depth knowledge about the many ...

Having secured one of last year’s largest funding rounds, Formation Bio is eyeing up to 545 million euros from a licensing deal with Sanofi.